OTUD1 and non-small cell lung carcinoma: However, OTUD1 conferred erlotinib susceptibility in NSCLC by repressing the nuclear translocation of YAP1 (112).OTUD5 knockdown also potentiated resistance to doxorubicin and cisplatin in NSCLC cells (113).